MEDICALGORITHMICS SA (19/2024) Dopuszczenie i warunkowe wprowadzenie do obrotu na rynku podstawowym prowadzonym przez GPW akcji serii J Spółki. Ustalenie daty pierwszego notowania akcji serii J Spółki po ich asymilacji z akcjami znajdującymi się w obrocie

Admission

and conditional introduction of the Company's series J shares to trading

on the main market of the WSE. Setting the date of the first listing of

the Company's series J shares after their assimilation with shares

traded on the main market.

Current

Report No.: 19/2024

Date:

September 13, 2024

Legal

Basis: Article 56(1)(2) of the Act on Public Offering - Current and

Periodic Information

The

Management Board of Medicalgorithmics S.A. with its registered office in

Warsaw (the "Issuer", the "Company"),

hereby announces that on 13 September 2024 it received information on

the adoption of Resolution No. 1134/2024 of the Management Board of the

Warsaw Stock Exchange S.A. ("WSE") on the admission and

introduction to exchange trading on the WSE Main Market of series J

bearer ordinary shares of Medicalgorithmics S.A. (the "Resolution").

Pursuant

to the Resolution, 1,194,331

(one million one hundred and ninety-four

thousand three hundred and thirty-one) series J bearer common shares of

the Company carrying ISIN code PLMDCLG00056

(the "Shares"), with a nominal value of 0.10 (ten groszy)

each, were admitted to trading on the main market.

Pursuant

to the Resolution, the Shares will be listed on the main market as of

September 20, 2024, subject to the assimilation of the Shares by the

National Securities Depository (Krajowy Depozyt Papierów Wartościowych

S.A.) on September 20, 2024, with the Company's shares traded on the

stock exchange, under the code PLMDCLG00015. The Company will announce

the assimilation of the Shares in a separate current report.

The

Company reminds that the Shares were issued in accordance with the

Resolution No. 4 of the Company's Extraordinary General Meeting of

October 28, 2022 Increase of the Company's share capital through issue

of series I, J, K and L shares; waiver of existing shareholders'

subscription rights; private subscription offer for a designated entity;

and change of Article 5 (1) and (2) of the Articles of Association. The

shares were registered with the National Securities Depository on March

7, 2023, as the Company announced in current report number 8/2023 on

March 8, 2023.

The

Company reminds that in the current report No. 55/2022 it informed on

October 1, 2022, that 4,976,384 Shares were acquired by Biofund Capital

Management LLC with its registered office in Miami (USA). These shares

are to be introduced to trading under the applicable exceptions to the

obligation to prepare an issue prospectus, and the planned date of

introducing all these shares to trading has been set at the end of 2026.

More information on page: http://biznes.pap.pl/en/reports/espi/all,0,0,0,1

kom espi zdz